• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Proc Natl Acad Sci U S A . Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicr

tetano

Editor, Senior Moderator
Proc Natl Acad Sci U S A


. 2023 Dec 26;120(52):e2311752120.
doi: 10.1073/pnas.2311752120. Epub 2023 Dec 22. Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants

Zhongfeng Ye[SUP] #[/SUP][SUP] 1 [/SUP], Srinivasa Reddy Bonam[SUP] #[/SUP][SUP] 2 [/SUP], Lindsay G A McKay[SUP] 3 [/SUP], Jessica A Plante[SUP] 2 4 [/SUP], Jordyn Walker[SUP] 2 4 [/SUP], Yu Zhao[SUP] 1 [/SUP], Changfeng Huang[SUP] 1 [/SUP], Jinjin Chen[SUP] 1 [/SUP], Chutian Xu[SUP] 1 [/SUP], Yamin Li[SUP] 5 [/SUP], Lihan Liu[SUP] 1 [/SUP], Joseph Harmon[SUP] 1 [/SUP], Shuliang Gao[SUP] 1 [/SUP], Donghui Song[SUP] 1 [/SUP], Zhibo Zhang[SUP] 1 [/SUP], Kenneth S Plante[SUP] 2 4 [/SUP], Anthony Griffiths[SUP] 3 [/SUP], Jianzhu Chen[SUP] 6 [/SUP], Haitao Hu[SUP] 2 [/SUP], Qiaobing Xu[SUP] 1 [/SUP]



Affiliations
Abstract

The emergence of highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that are resistant to the current COVID-19 vaccines highlights the need for continued development of broadly protective vaccines for the future. Here, we developed two messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccines, TU88mCSA and ALCmCSA, using the ancestral SARS-CoV-2 spike sequence, optimized 5' and 3' untranslated regions (UTRs), and LNP combinations. Our data showed that these nanocomplexes effectively activate CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cell responses and humoral immune response and provide complete protection against WA1/2020, Omicron BA.1 and BQ.1 infection in hamsters. Critically, in Omicron BQ.1 challenge hamster models, TU88mCSA and ALCmCSA not only induced robust control of virus load in the lungs but also enhanced protective efficacy in the upper respiratory airways. Antigen-specific immune analysis in mice revealed that the observed cross-protection is associated with superior UTRs [Carboxylesterase 1d (Ces1d)/adaptor protein-3β (AP3B1)] and LNP formulations that elicit robust lung tissue-resident memory T cells. Strong protective effects of TU88mCSA or ALCmCSA against both WA1/2020 and VOCs suggest that this mRNA-LNP combination can be a broadly protective vaccine platform in which mRNA cargo uses the ancestral antigen sequence regardless of the antigenic drift. This approach could be rapidly adapted for clinical use and timely deployment of vaccines against emerging and reemerging VOCs.

Keywords: lipid nanoparticle; lung tissue-resident memory T cells; mRNA vaccine; untranslated region.

 
Back
Top Bottom